AR045193A1 - Composicion de fexofenadina y proceso de preparacion - Google Patents
Composicion de fexofenadina y proceso de preparacionInfo
- Publication number
- AR045193A1 AR045193A1 ARP040102748A ARP040102748A AR045193A1 AR 045193 A1 AR045193 A1 AR 045193A1 AR P040102748 A ARP040102748 A AR P040102748A AR P040102748 A ARP040102748 A AR P040102748A AR 045193 A1 AR045193 A1 AR 045193A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally
- fexofenadine
- pharmaceutical composition
- hydroxypropyl cellulose
- substituted hydroxypropyl
- Prior art date
Links
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003592 fexofenadine Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title 1
- 239000008187 granular material Substances 0.000 abstract 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 2
- 239000008101 lactose Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000005550 wet granulation Methods 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composición farmacéutica que comprende fexofenadina o una sal farmacéuticamente aceptable de la misma, lactosa, una celulosa de hidroxipropilo sustituida baja y opcionalmente otros excipientes. Las composiciones de fexofenadina del presente muestran biodisponibilidad mejorada como se expresa como Cmax, la cantidad máxima de ingrediente activo encontrado en el plasma, o como AUC, el área bajo la curva de tiempo de concentración de plasma. Reivindicación 21: El uso de la composición según cualquier reivindicación precedente para la fabricación de un medicamento para el tratamiento de desordenes asociados con alergia. Reivindicación 22:Un método para preparar una composición farmacéutica según cualquiera de las reivindicaciones 1 a 3, dicho método comprendiendo: a) mezclar fexofenadina o una sal farmacéuticamente aceptable de la misma, lactosa, celulosa de hidroxipropilo sustituida baja, y opcionalmente uno o más excipientes para formar una premezcla; b) agregar un solvente y opcionalmente un agente tensioactivo para la premezcla formada en el paso a) para formar una granulación húmeda; y c) secar la granulación húmeda para formar gránulos secos; d) mezclar opcionalmente los gránulos secos; e) opcionalmente agregar una cantidad adicional de celulosa de hidroxipropilo sustituida baja; y f) mezclar al menos un excipiente con los gránulos secos para formar una composición farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/631,874 US20050065183A1 (en) | 2003-07-31 | 2003-07-31 | Fexofenadine composition and process for preparing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045193A1 true AR045193A1 (es) | 2005-10-19 |
Family
ID=34135544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102748A AR045193A1 (es) | 2003-07-31 | 2004-08-02 | Composicion de fexofenadina y proceso de preparacion |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050065183A1 (es) |
| EP (1) | EP1651218A1 (es) |
| JP (1) | JP2007500682A (es) |
| AR (1) | AR045193A1 (es) |
| AU (1) | AU2004262914A1 (es) |
| BR (1) | BRPI0413186A (es) |
| CR (1) | CR8220A (es) |
| EC (1) | ECSP066327A (es) |
| NO (1) | NO20060991L (es) |
| RU (1) | RU2006105720A (es) |
| WO (1) | WO2005013987A1 (es) |
| ZA (1) | ZA200600519B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20033019A3 (cs) * | 2001-04-09 | 2004-07-14 | Teva Pharmaceutical Industries Ltd. | Polymorfní formy chloridu fexofenadinu |
| JP2007517056A (ja) | 2003-12-29 | 2007-06-28 | セプラコア インコーポレーテッド | ピロール及びピラゾールｄａａｏ阻害剤 |
| US20050256163A1 (en) * | 2004-04-26 | 2005-11-17 | Ilan Kor | Crystalline forms of fexofenadine hydrochloride and processes for their preparation |
| JP2008514641A (ja) * | 2004-09-28 | 2008-05-08 | テバ ファーマシューティカル インダストリーズ リミティド | 結晶形フェキソフェナジン、およびその調製方法 |
| US20070048373A1 (en) * | 2005-08-30 | 2007-03-01 | Cima Labs Inc. | Dried milled granulate and methods |
| US20070148245A1 (en) * | 2005-12-22 | 2007-06-28 | Ilan Zalit | Compressed solid dosage forms with drugs of low solubility and process for making the same |
| EP1808163A1 (en) * | 2005-12-22 | 2007-07-18 | Teva Pharmaceutical Industries Ltd. | Compressed solid dosage forms with drugs of low solubility and process for making the same |
| CA2626234A1 (en) * | 2005-12-22 | 2007-06-28 | Teva Pharmaceutical Industries Ltd. | Compressed solid dosage forms with drugs of low solubility and process for making the same |
| WO2007133802A2 (en) * | 2006-05-15 | 2007-11-22 | Acadia Pharmaceuticals Inc. | Pharmaceutical formulations of pimavanserin |
| RU2453315C2 (ru) * | 2010-08-17 | 2012-06-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтическая композиция для лечения аллергических заболеваний |
| WO2012040082A2 (en) * | 2010-09-21 | 2012-03-29 | Intekrin Therapeutics, Inc. | Antidiabetic solid pharmaceutical compositions |
| JP2013119540A (ja) * | 2011-12-08 | 2013-06-17 | Nipro Corp | 固形医薬組成物およびその製造法 |
| JP6040218B2 (ja) * | 2012-02-23 | 2016-12-07 | フロイント産業株式会社 | 口腔内崩壊錠用直打賦形剤及びその製造方法、並びに口腔内崩壊錠 |
| JP6184727B2 (ja) * | 2013-04-15 | 2017-08-23 | ロート製薬株式会社 | 医薬組成物 |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| CN106137989A (zh) * | 2016-07-20 | 2016-11-23 | 南通雅本化学有限公司 | 一种基于盐酸非索非那定的药物组合物 |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| JP6410895B2 (ja) * | 2017-07-26 | 2018-10-24 | ロート製薬株式会社 | 医薬組成物 |
| JP2019011350A (ja) * | 2018-09-25 | 2019-01-24 | ロート製薬株式会社 | 医薬組成物 |
| WO2022123511A1 (en) * | 2020-12-11 | 2022-06-16 | Cellix Bio Private Limited | A composition comprising fexofenadine |
| GB2629127A (en) | 2022-08-31 | 2024-10-23 | Novumgen Ltd | An orodispersible tablet of fexofenadine and its process of preparation |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3878217A (en) * | 1972-01-28 | 1975-04-15 | Richardson Merrell Inc | Alpha-aryl-4-substituted piperidinoalkanol derivatives |
| JPS52151717A (en) * | 1976-06-09 | 1977-12-16 | Shionogi & Co Ltd | Sugar coating on solid preparations |
| US4285957A (en) * | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof |
| US4254129A (en) * | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
| JPS6183123A (ja) * | 1984-09-28 | 1986-04-26 | Taisho Pharmaceut Co Ltd | 抗喘息剤 |
| US4996061A (en) * | 1987-10-07 | 1991-02-26 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol-decongestant combination |
| US4929605A (en) * | 1987-10-07 | 1990-05-29 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol derivatives |
| HU223774B1 (hu) * | 1992-05-11 | 2005-01-28 | Merrell Dow Pharmaceuticals Inc. | Terfenadinszármazékok alkalmazása antihisztamin hatású gyógyszerkészítmények előállítására |
| EP0703902B1 (en) * | 1993-06-24 | 1998-12-16 | Albany Molecular Research, Inc. | Process for the production of piperidine derivatives |
| WO1996026726A1 (en) * | 1995-02-28 | 1996-09-06 | Hoechst Marion Roussel, Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
| US6576636B2 (en) * | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| JPH09315971A (ja) * | 1996-05-28 | 1997-12-09 | Daito Kk | テルフェナジン含有錠剤製剤 |
| AU718350B2 (en) * | 1996-11-15 | 2000-04-13 | Ajinomoto Co., Inc. | Tablet composition |
| HRP980532B1 (en) * | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
| AU2199500A (en) * | 1998-12-23 | 2000-07-31 | Alza Corporation | Gastric retention dosage form having multiple layers |
| EP1054019A1 (en) * | 1999-05-18 | 2000-11-22 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose |
| US6500459B1 (en) * | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
| US6375982B1 (en) * | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
| US20030021849A1 (en) * | 2001-04-09 | 2003-01-30 | Ben-Zion Dolitzky | Polymorphs of fexofenadine hydrochloride |
| US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
-
2003
- 2003-07-31 US US10/631,874 patent/US20050065183A1/en not_active Abandoned
-
2004
- 2004-07-30 WO PCT/EP2004/008600 patent/WO2005013987A1/en not_active Ceased
- 2004-07-30 AU AU2004262914A patent/AU2004262914A1/en not_active Abandoned
- 2004-07-30 EP EP04763678A patent/EP1651218A1/en not_active Withdrawn
- 2004-07-30 RU RU2006105720/15A patent/RU2006105720A/ru unknown
- 2004-07-30 JP JP2006521550A patent/JP2007500682A/ja not_active Withdrawn
- 2004-07-30 BR BRPI0413186-0A patent/BRPI0413186A/pt not_active Application Discontinuation
- 2004-08-02 AR ARP040102748A patent/AR045193A1/es unknown
-
2006
- 2006-01-18 ZA ZA200600519A patent/ZA200600519B/en unknown
- 2006-01-27 EC EC2006006327A patent/ECSP066327A/es unknown
- 2006-01-30 CR CR8220A patent/CR8220A/es not_active Application Discontinuation
- 2006-02-28 NO NO20060991A patent/NO20060991L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20060991L (no) | 2006-04-28 |
| WO2005013987A1 (en) | 2005-02-17 |
| ECSP066327A (es) | 2006-07-28 |
| BRPI0413186A (pt) | 2006-10-03 |
| US20050065183A1 (en) | 2005-03-24 |
| AU2004262914A1 (en) | 2005-02-17 |
| ZA200600519B (en) | 2007-01-31 |
| RU2006105720A (ru) | 2007-09-10 |
| JP2007500682A (ja) | 2007-01-18 |
| EP1651218A1 (en) | 2006-05-03 |
| CR8220A (es) | 2006-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045193A1 (es) | Composicion de fexofenadina y proceso de preparacion | |
| AR014133A1 (es) | Procedimiento para fabricar tabletas de dispersion rapida para administracion oral y una formulacion de dichas tabletas | |
| PE20030823A1 (es) | Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo | |
| ECSP024401A (es) | Procedimiento para preparar una composicion | |
| RU2017133990A (ru) | Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона | |
| CR9292A (es) | Comprimidos con dispersion mejorada de la sustancia farmacologica | |
| RU2017106795A (ru) | Новые составы ингибитора тирозинкиназы брутона | |
| AR037642A1 (es) | Preformulacion farmaceutica para tabletado, y procedimiento para su preparacion | |
| UY29410A1 (es) | Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones. | |
| AR037260A1 (es) | Formulaciones de proteinas de liberacion sostenida acuosas | |
| PE20250018A1 (es) | Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida | |
| ECSP034826A (es) | Método para fabricar una composición farmacéutica de dosis baja | |
| MX2020010834A (es) | Formulacion solida de mezclas insecticidas. | |
| RU2015109566A (ru) | НОВЫЕ ЭКСТРАКТЫ ИЗ CYNARA SCOLYMUS, COFFEA spp. И OLEA EUROPAEA ДЛЯ ЛЕЧЕНИЯ МЕТАБОЛИЧЕСКОГО СИНДРОМА | |
| EA201170784A1 (ru) | Гранулы тамсулозина для фиксированной комбинации | |
| PH12022550430A1 (en) | Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same | |
| CO2023002650A2 (es) | Formas farmacéuticas sólidas de palbociclib | |
| RU2016106328A (ru) | Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления | |
| CN102846573B (zh) | 水飞蓟宾双层缓释片及其制备方法 | |
| RU2012124704A (ru) | Лекарственное средство на основе сухих экстрактов лекарственных растений и способ его получения (варианты) | |
| PE20231943A1 (es) | Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma | |
| CN102641240B (zh) | 一种苦柯胺b盐注射剂及其制备方法 | |
| EA201190091A1 (ru) | Активируемый влагой способ грануляции | |
| MX337488B (es) | Granulos con alto contenido de ibuprofeno sodico, su preparacion y su uso en preparar formas de dosificacion solidas no efervescentes. | |
| AR128113A1 (es) | Composiciones que contienen fexofenadina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |